Evidence map›Paper›PMID 26071541›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2015

Substance P induces cardioprotection in ischemia-reperfusion via activation of AKT.

Shaiban Jubair, Jianping Li, Heather M Dehlin, Edward J Manteufel, Paul H Goldspink, Scott P Levick, Joseph S Janicki

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Substance P Inhibits the Collagen Synthesis of Rat Myocardial Fibroblasts Induced by Ang II.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shaiban JubairCell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina;
Jianping LiCell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina;
Heather M DehlinPharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin; and.
Edward J ManteufelPharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin; and.
Paul H GoldspinkCardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin; and Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin.
Scott P LevickPharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin; Cardiovascular Center, Medical College of Wisconsin, Milwaukee, Wisconsin; and.
Joseph S JanickiCell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, South Carolina; Joseph.Janicki@uscmed.sc.edu.
Medical College of Wisconsin · USUniversity of South Carolina · US

Funding

Neuro-immune Modulation of Cardiac Mast Cell-Mediated Myocardial RemodelingR00HL093215 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI LEVICK, SCOTT P · 2011 to 2013
$709k
NHLBI NIH HHS R00-HL-093215NHLBI NIH HHS R21-HL-59981
6 · The paper itself

Abstract

Accumulating evidence indicates that substance P is cardioprotective following ischemia-reperfusion primarily due to its potent coronary vasodilator actions. However, an anti-apoptotic effect of substance P has been observed in tenocytes following ischemia, which involved activation of the AKT pathway. This suggests the possibility that substance P also provides cardioprotection via direct actions to activate AKT in myocardial cells. The purpose of this study was to test the hypothesis that substance P attenuates ischemia-related cell death via direct effects on myocardial cells by activating cell survival pathways. Seven-week-old male Sprague-Dawley rats, anesthetized with intraperitoneal pentobarbital sodium (100 mg/kg), were used. The ability of substance P to prevent cellular damage was assessed following ischemia-reperfusion in an isolated heart preparation and in short-term hypoxia without reperfusion using a left ventricular tissue slice culture preparation. In addition, the NK-1 receptor and AKT involvement was assessed using the NK-1 receptor antagonist L732138 and the AKT inhibitor LY294002. The results indicate that substance P reduced the ischemia-related release of lactate dehydrogenase in both preparations and the degree of apoptosis and necrosis in the hypoxic left ventricular slices, indicating its ability to attenuate cell damage; and induced AKT phosphorylation, with both the AKT inhibitor and NK-1 receptor antagonist preventing the increased phosphorylation of AKT and the ability of substance P to attenuate hypoxic cellular damage. It is concluded that substance P reduces ischemia/hypoxia-induced myocardial cell death by acting directly on cardiac cells to initiate cell survival pathways via the NK-1 receptor and AKT.

Indexed as

AnimalsCardiotonic AgentsCell HypoxiaCells, CulturedMaleMiceMice, Inbred C57BLMyocardial Reperfusion InjuryMyocytes, CardiacProto-Oncogene Proteins c-aktRatsRats, Sprague-DawleyReceptors, Neurokinin-1Signal TransductionSubstance PCardiotonic AgentsProto-Oncogene Proteins c-aktReceptors, Neurokinin-1Substance PAKT inhibitorapoptosisisolated heart global ischemia and reperfusionlactate dehydrogenaseleft ventricular tissue slice cultureNK-1 receptor antagonist

Identifiers

PMID26071541
PMCPMC4537946
OpenAlexW2265669797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.